(MedPage Today) – Drugmaker GSK announced Wednesday that the FDA has approved zidacemtinib (Zydetro) for previously treated adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Zidesamtinib is a next generation…
Trending
- Between price gouging and diarrhea-causing parasites, lettuce is making trouble at some restaurants
- Antihistamines banned for eczema
- What Britain’s air-con controversy tells us about fighting climate change
- Resume of Lindsay Clancy’s ex-husband testifying about the day he murdered her three children
- Hospice’s poor reputation amid fraud crisis will harm patients, industry experts warn
- Can trees fall due to heat wave?
- More than half of England officially hit by drought – Environment Agency
- Uninsured but fearless, one surgical patient searched the world for a deal
FDA greenlights next-generation ROS1 inhibitor for lung cancer
By 
Add A Comment